• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Copley Scientific banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Nasus Pharma says its Taffix intranasal HPMC significantly reduced SARS-CoV-2 infection in real world superspreader event

Israeli biopharma company Nasus Pharma says that it provided its Taffix intranasal hydroxypropyl methylcellulose (HPMC) powder to members of a synagogue for use during Rosh Hashana celebrations, and worshippers who used Taffix were infected with SARS-CoV-2 at one quarter the rate of those who did not use the nasal powder. The members of the synagogue were in close contact for a total of 14 hours over 2 days. According to Nasus, only 2 out of 83 worshippers who used Taffix were infected compared to 16 out of 160 who did not use Taffix within 14 days after the holiday services.

The company, which is marketing Taffix as protection against viruses in Israel and in Europe, says that the HPMC powder forms an acidic gel layer in the nose that provides both mechanical and chemical protection against viruses for 5 hours. Nasus is also developing intranasal dry powder formulations of naloxone and epinephrine.

Nasus Pharma CEO Dalia Megiddo commented, “These important results conform with prior in vitro studies performed with Taffix that proved its robust activity against the transmission of SARS-CoV-2. This is the first clinical real life data showing that the use of Taffix is highly effective even in the worst-case scenario of a super spread event in the heart of the worst hit city in Israel. Reducing the infection risk by 75% or even 100% can dramatically change the means to fight the worst epidemic humanity have witnessed in close to a 100 years.”

Executive Chairman of the Board Udi Gilboa said, “This promising clinical data reinforces the potential of Taffix to become an important solution and the leading additional layer of protection that will enable the resuming of social and economic activities in a much safer manner.”

Read the Nasus Pharma press release.

Share

published on October 13, 2020

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Merxin We Make Inhalers banner
    © 2025 OINDPnews